Viridian Therapeutics, Inc.\DE (VRDN) Times Interest Earned (2013 - 2026)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Times Interest Earned of -$33.56 for Q1 2026, up 80.34% year-over-year from -$18.61 in Q1 2025, and up 1.97% quarter-over-quarter from -$34.23 in Q4 2025.
Viridian Therapeutics, Inc.\DE (VRDN) Times Interest Earned (2013 - 2026) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Times Interest Earned history runs 14 years deep, the most recent figure standing at -$33.56 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 80.34% year-over-year to -$33.56; the TTM figure through Mar 2026 stood at -$47.28 (up 76.33% YoY), while the FY2025 annual figure was -$1.15, up 20.02% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$33.56, up from -$34.23 in the prior quarter.
- The five-year high for Times Interest Earned was $7009.4 in Q4 2022, with the low at -$624.8 in Q4 2024.
- The 5-year median for Times Interest Earned is -$103.14 (2024), against an average of $287.14.
- The sharpest annual moves came in 2022 and 2025: Times Interest Earned soared 4920.62% in 2022, then sank 1228.72% in 2025.
- Viridian Therapeutics, Inc.\DE's Times Interest Earned stood at $7009.4 in 2022, then tumbled by 102.55% to -$178.7 in 2023, then tumbled by 249.65% to -$624.8 in 2024, then jumped by 94.52% to -$34.23 in 2025, then gained by 1.97% to -$33.56 in 2026.
- Business Quant data shows VRDN's Times Interest Earned at -$33.56 in Q1 2026, -$34.23 in Q4 2025, and -$71.45 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Viridian Therapeutics, Inc.\DE | 2.50 Bn | 2.50 Bn | - | -2.94 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.94 |
| Mar 31, 2026 | -33.56 |
| Dec 31, 2025 | -34.23 |
| Sep 30, 2025 | -71.45 |
| Jun 30, 2025 | -22.61 |
| Mar 31, 2025 | -170.67 |
| Dec 31, 2024 | -624.80 |
| Sep 30, 2024 | -5.38 |
| Jun 30, 2024 | -120.92 |
| Mar 31, 2024 | -51.38 |
| Dec 31, 2023 | -178.70 |
| Sep 30, 2023 | -85.37 |
| Jun 30, 2023 | -357.08 |
| Mar 31, 2023 | -362.37 |
| Dec 31, 2022 | 7,009.43 |
| Sep 30, 2022 | -148.93 |
| Jun 30, 2022 | -147.82 |
| Dec 31, 2021 | -145.41 |
| Mar 31, 2021 | -46.29 |
| Dec 31, 2020 | -292.25 |